Art. -Nr.: HY-78131

Ibuprofen

(Synonyms: (±)-Ibuprofen)

23 Cited Publications

Kundenbewertung

Based on 23 publication(s) in Google Scholar

Ibuprofen ((±)-Ibuprofen) is a potent, orally active, selective COX-1 inhibitor with an IC₅₀ value of 13 μM. Ibuprofen inhibits cell proliferation, angiogenesis, and induces cell apoptosis. Ibuprofen is a nonsteroidal anti-inflammatory agent and a nitric oxide (NO) donor. Ibuprofen ((±)-Ibuprofen) can be used in the research of pain, swelling, inflammation, infection, immunology, cancers.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.97%
CAS. Nr.: 15687-27-1
Formel: C₁₃H₁₈O₂
Molecular Weight:206.28

Speicherung:

Store at room temperature 3 years.

In solvent -80°C, 2 years , -20°C, 1 year

Ibuprofen Chemical Structure

CAS. Nr.: 15687-27-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (23)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

COX-1

13 μM (IC₅₀)

COX-2

370 μM (IC₅₀)

Alle COX Isoform-spezifische Produkte anzeigen :

Alle Parasite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>50 μM Compound: Ibuprofen	Cytotoxicity against human A549 cells measured after 24 to 72 hrs by MTT assay Cytotoxicity against human A549 cells measured after 24 to 72 hrs by MTT assay	[PMID: 37482018]
Bel-7402	IC₅₀	>100 μM Compound: Ibuprofen	Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
Bel7402/5-FU	IC₅₀	>100 μM Compound: Ibuprofen	Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
BGC-823	IC₅₀	>50 μM Compound: Ibuprofen	Cytotoxicity against human BGC-823 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human BGC-823 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
BGC-823	IC₅₀	>50 μM Compound: Ibuprofen	Cytotoxicity against human BGC-823 cells measured after 24 to 72 hrs by MTT assay Cytotoxicity against human BGC-823 cells measured after 24 to 72 hrs by MTT assay	[PMID: 37482018]
Caco-2	IC₅₀	>50 μM Compound: Ibuprofen	Cytotoxicity against human Caco2 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
CHO	IC₅₀	8 μM Compound: Ibuprofen	TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells TP_TRANSPORTER: inhibition of Adefovir uptake in OAT1-expressing CHO cells	[PMID: 10991954]
CHO	IC₅₀	200 μM Compound: 1	Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA Modulation of gamma-secretase-mediated cleavage of human APP expressed in CHO cells with human presenilin-1 assessed as inhibition of amyloid beta42 production after 24 hrs by ELISA	[PMID: 20503989]
CHO	IC₅₀	200 μM Compound: 1	Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA Modulation of gamma-secretase expressed in CHO cells co-expressing human APP and wild type human presenilin-1 assessed as inhibition of amyloid beta42 production by ELISA	[PMID: 21873070]
COS-7	IC₅₀	>1000 μM Compound: Ibuprofen	Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against African green monkey COS7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
HCT-116	IC₅₀	448 μM Compound: IB	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 20171760]
HCT-15	IC₅₀	>1000 μM Compound: Ibuprofen	Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
HeLa	IC₅₀	>50 μM Compound: Ibuprofen	Cytotoxicity against human HeLa cells measured after 24 to 72 hrs by MTT assay Cytotoxicity against human HeLa cells measured after 24 to 72 hrs by MTT assay	[PMID: 37482018]
HT-29	IC₅₀	552 μM Compound: IB	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 20171760]
HT-29	IC₅₀	>50 μM Compound: Ibu	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
HT-29	IC₅₀	>50 μM Compound: Ibu	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
HT-29	IC₅₀	>50 μM Compound: Ibu	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
Huh-7	IC₅₀	37.2 μM Compound: Ibu	Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay Cytotoxicity against human HuH7 cells assessed as growth inhibition after 72 hrs by sulforhodamine B assay	[PMID: 26810835]
K562	IC₅₀	>1000 μM Compound: Ibuprofen	Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
L02	IC₅₀	>100 μM Compound: Ibuprofen	Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay	[PMID: 28301815]
MCF7	IC₅₀	92.14 μM Compound: Ibuprofen	Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
MCF7	IC₅₀	>50 μM Compound: Ibuprofen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
MCF7	IC₅₀	>50 μM Compound: 6	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35468536]
MCF7	IC₅₀	>50 μM Compound: Ibuprofen	Cytotoxicity against human MCF7 cells measured after 24 to 72 hrs by MTT assay Cytotoxicity against human MCF7 cells measured after 24 to 72 hrs by MTT assay	[PMID: 37482018]
MDA-MB-231	IC₅₀	>50 μM Compound: Ibu	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
MDA-MB-231	IC₅₀	>50 μM Compound: Ibu	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
MDA-MB-231	IC₅₀	>50 μM Compound: Ibu	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
Neutrophil	IC₅₀	27.5 μM Compound: ibuprofen	Inhibition of fMLP-induced superoxide production in human neutrophils Inhibition of fMLP-induced superoxide production in human neutrophils	[PMID: 17559265]
Neutrophil	IC₅₀	32.55 μM Compound: ibuprofen	Antiinflammatory activity in human neutrophils assessed as fMLP-induced superoxide release after 5 mins by spectrometry Antiinflammatory activity in human neutrophils assessed as fMLP-induced superoxide release after 5 mins by spectrometry	[PMID: 17822293]
Neutrophil	IC₅₀	12.1 μM Compound: Ibuprofen	Immunomodulatory activity in polymorphoneutrophils assessed as inhibition of luminol-induced oxidative burst by chemiluminescence assay Immunomodulatory activity in polymorphoneutrophils assessed as inhibition of luminol-induced oxidative burst by chemiluminescence assay	[PMID: 18950230]
Neutrophil	IC₅₀	27.53 μM Compound: ibuprofen	Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP-indcued superoxide production after 5 mins Antiinflammatory activity in human neutrophils assessed as inhibition of fMLP-indcued superoxide production after 5 mins	[PMID: 20839880]
PANC-1	IC₅₀	>50 μM Compound: Ibu	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
PANC-1	IC₅₀	>50 μM Compound: Ibu	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
PANC-1	IC₅₀	>50 μM Compound: Ibu	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]
PC-3	IC₅₀	>1000 μM Compound: Ibuprofen	Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
PC-3	IC₅₀	>50 μM Compound: Ibuprofen	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 33799070]
RAW264.7	IC₅₀	0.86 μM Compound: Ibuprofen	Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production treated prior to LPS challenge by enzyme immunoassay Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production treated prior to LPS challenge by enzyme immunoassay	[PMID: 24656662]
RAW264.7	IC₅₀	0.39 μM Compound: Ibuprofen	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated PGE2 production by ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated PGE2 production by ELISA	[PMID: 28408221]
RAW264.7	IC₅₀	1483.87 μM Compound: Ibuprofen	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production by ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production by ELISA	[PMID: 28408221]
RAW264.7	IC₅₀	3309.84 μM Compound: Ibuprofen	Cytotoxicity against mouse RAW264.7 cells by MTT assay Cytotoxicity against mouse RAW264.7 cells by MTT assay	[PMID: 28408221]
RAW264.7	IC₅₀	54.5 μM Compound: Ibuprofen	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production by measuring nitrite accumulation by Griess method	[PMID: 28561586]
RAW264.7	IC₅₀	14.4 μM Compound: Ibuprofen	Anti-inflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as reduction in IL1beta protein expression level after 24 hrs by ELISA Anti-inflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as reduction in IL1beta protein expression level after 24 hrs by ELISA	[PMID: 34890996]
RAW264.7	IC₅₀	2.1 μM Compound: Ibuprofen	Anti-inflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as reduction in TNFalpha protein expression level after 24 hrs by ELISA Anti-inflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as reduction in TNFalpha protein expression level after 24 hrs by ELISA	[PMID: 34890996]
RAW264.7	EC₅₀	26.74 μM Compound: IBP	Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production	[PMID: 37925088]
RAW264.7	IC₅₀	>1000 μM Compound: IBP	Cytotoxicity against mouse RAW264.7 cells assessed as cell growth inhibition by CCK-8 colorimetric assay Cytotoxicity against mouse RAW264.7 cells assessed as cell growth inhibition by CCK-8 colorimetric assay	[PMID: 37925088]
RBL-1	IC₅₀	2 μM Compound: 10	Inhibition of Prostaglandin G/H synthase in intact RBL-1 cell line Inhibition of Prostaglandin G/H synthase in intact RBL-1 cell line	[PMID: 2115586]
Sf21	IC₅₀	290.9 μM Compound: Ibuprofen	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	598.6 μM Compound: Ibuprofen	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
SK-LU-1	IC₅₀	90.61 μM Compound: Ibuprofen	Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human SKLU1 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
SW480	IC₅₀	>50 μM Compound: Ibuprofen	Cytotoxicity against human SW480 cells measured after 24 to 72 hrs by MTT assay Cytotoxicity against human SW480 cells measured after 24 to 72 hrs by MTT assay	[PMID: 37482018]
TERT-RPE1	IC₅₀	>40 μM Compound: 6	Cytotoxicity against human RPE-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human RPE-1 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 35468536]
U-251	IC₅₀	>1000 μM Compound: Ibuprofen	Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human U251 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 32527536]
UACC-903	IC₅₀	>50 μM Compound: Ibu	Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 26750401]
UACC-903	IC₅₀	>50 μM Compound: Ibu	Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26750401]
UACC-903	IC₅₀	>50 μM Compound: Ibu	Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human UACC-903 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26750401]

In Vitro

Ibuprofen (24 h) inhibits COX-1 and COX-2 activity with IC₅₀ values of 13 μM and 370 μM^[1].
Ibuprofen (500 μM, 48 h) inhibits cell proliferation and angiogenesis, and induces apoptosis in AGS cells (Adenocarcinoma gastric cell line)^[2].
Ibuprofen (500 μM, 48 h) downregulates transcription of Akt, VEGF-A, PCNA, Bcl2, OCT3/4 and CD44 genes, but upregulates RNA levels of wild type P53 and Bax genes in AGS cell^[2].
Ibuprofen (500 μM, 24 h) restores microtubule reformation, microtubule-dependent intracellular cholesterol transport, and induces extension of microtubules to the cell periphery in both cystic fibrosis (CF) cell models and primary CF nasal epithelial cells^[3].
Ibuprofen (500 μM, 24 h) enhances UV-induced cell death in MCF-7 cells and MDA-MB-231 cells by a photosensitization process^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

AGS cells
Concentration:

100-1000 μM
Incubation Time:

24 h, 48 h
Result:

Inhibited AGS cell viability with IC₅₀ values of 630 μM (trypan blue staining, 24 h), 456 μM (neutral red assay, 24 h), 549 μM (trypan blue staining, 48 h) and 408 μM (neutral red assay, 48 h).

In Vivo

Ibuprofen (300 mg/kg; p.o.; daily, for 14 days) reduces overall tumor growth and enhances anti-tumor immune characteristics without adverse autoimmune reactions in a model of postpartum breast cancer^[5].
Ibuprofen (60 mg/kg; i.h.; every second day for 15 days) reduces the risk of neuropathy in a rat model of chronic Oxaliplatin induced peripheral neuropathy^[6].
Ibuprofen (20 mg/kg; p.o.; every 12 hours, 5 doses total) decreases muscle growth (average muscle fiber cross-sectional area) without affecting regulation of supraspinatus tendon adaptions to exercise^[7].
Ibuprofen (35 mg/kg; p.o.; twice daily) attenuates the Inflammatory response to pseudomonas aeruginosa in a rat model of chronic pulmonary infection^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Syngeneic (D2A1) orthotopic Balb/c mouse model of PPBC (postpartum)^[5]
Dosage:

300 mg/kg, daily for 14 days
Administration:

Fed in animal feedings (added to pulverized standard chow and mixed dry, then mixed with water, made into chow pellets and dried thoroughly)
Result:

Suppresed tumor growth, reduced presence of immature monocytes and increased numbers of T cells.
Enhanced Th1 associated cytokines as well as promoted tumor border accumulation of T cells.

Animal Model:

Oxaliplatin‑induced peripheral neuropathy^[6]
Dosage:

60 mg/kg, every second day for 15 days
Administration:

Subcutaneous injection
Result:

Lowered sensory nerve conduction velocity (SNCV).

Chemical Information

CAS. Nr. 15687-27-1
Appearance Solid
Molecular Weight 206.28
Formel C₁₃H₁₈O₂
Color White to off-white
SMILES

OC(C(C1=CC=C(CC(C)C)C=C1)C)=O
Synonyms

(±)-Ibuprofen
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Store at room temperature 3 years

In solvent	-80°C	2 years
	-20°C	1 year

Publications (23)

All In Vivo Efficacy StudyCell Proliferation/Viability AssayCell Migration/Invasion AssayFlow CytometryBio/Physico-chemical AssayWB

Sort by:

Journal Impact Factor

Biomaterials

GSH-activable and cytolytic iPep-coupled immune nanoagonist for cancer synergetic therapy. [Abstract]

2025 May 12:322:123402. PMID: 40373515
Phytomedicine

Prim-O-glucosycimifugin attenuates liver injury in septic mice by inhibiting NLRP3 inflammasome/caspase-1 signaling cascades in macrophages. [Abstract]

2022 Nov:106:154427. PMID: 36088791
J Hazard Mater Lett

2025 Nov.
Int J Biol Macromol

Molecular interaction of abemaciclib with human serum albumin: Insights from spectroscopy, microscopy, and computational approaches. [Abstract]

2025 Dec 9;337(Pt 2):149613. PMID: 41380878
Plant Physiol

The MdSP1-MdANK immune module activated by effector SyCD1 enhances Malus domestica resistance to Valsa mali. [Abstract]

2026 Mar 2;200(3):kiag108. PMID: 41757702
Cell Rep

LAMP2A-mediated neuronal hyperexcitability by enhancing NKAβ1 degradation underlies depression-induced allodynia. [Abstract]

2025 Apr 2;44(4):115489. PMID: 40178973
Cell Rep

A Central Amygdala Input to the Parafascicular Nucleus Controls Comorbid Pain in Depression. [Abstract]

2019 Dec 17;29(12):3847-3858.e5. PMID: 31851918

Ibuprofen purchased from MedChemExpress. Usage Cited in: Cell Rep. 2019 Dec 17;29(12):3847-3858.e5. [Abstract]

Effects of Ibuprofen (10 mg/kg, i.p.) or indomethacin (10 mg/kg, i.p.) on pain thresholds at day 3 after CFA treatment.

Ibuprofen purchased from MedChemExpress. Usage Cited in: Cell Rep. 2019 Dec 17;29(12):3847-3858.e5. [Abstract]

Effects of Ibuprofen (10 mg/kg, i.p.), Indomethacin, Gabapentin, or Lidocaine on pain thresholds of CRS 3W mice.
Biochem Pharmacol

The 'ABC' of split-nanoluciferase HIF heterodimerization bioassays: Applications, Benefits & Considerations. [Abstract]

2024 Aug 9:116478. PMID: 39128589
Inflammopharmacology

Ibuprofen inhibits anaplastic thyroid cells in vivo and in vitro by triggering NLRP3-ASC-GSDMD-dependent pyroptosis. [Abstract]

2024 Feb;32(1):733-745. PMID: 37999895

Ibuprofen purchased from MedChemExpress. Usage Cited in: Inflammopharmacology. 2024 Feb;32(1):733-745. [Abstract]

The inhibitory effect of Ibuprofen (0-3 mM, 48 h) on the proliferation of C643 and OCUT-2C cells was detected by CCK8 assay.

Ibuprofen purchased from MedChemExpress. Usage Cited in: Inflammopharmacology. 2024 Feb;32(1):733-745. [Abstract]

Transwell assay, cells were treated with various concentrations of Ibuprofen (C643 at 0, 0.5, 1, and 1.5 mM; OCUT-2C at 0, 1, 2, and 3 mM) for 48 h view cell invasion abilities.

Ibuprofen purchased from MedChemExpress. Usage Cited in: Inflammopharmacology. 2024 Feb;32(1):733-745. [Abstract]

Wound healing assay, cells were treated with different concentrations of Ibuprofen (C643 at 0, 0.5, 1, and 1.5 mM; OCUT-2C at 0, 1, 2, and 3 mM) for 48 h view cell migration abilities.

Ibuprofen purchased from MedChemExpress. Usage Cited in: Inflammopharmacology. 2024 Feb;32(1):733-745. [Abstract]

Flow cytometry analysis of ATC cells treated with different Ibuprofen (0-3 mM) concentrations for 48 h stained with Annexin V-FITC and PI.

Ibuprofen purchased from MedChemExpress. Usage Cited in: Inflammopharmacology. 2024 Feb;32(1):733-745. [Abstract]

The effect of Ibuprofen (0-1.5 mM) on LDH activity in C643 and OCUT-2C cells.

Ibuprofen purchased from MedChemExpress. Usage Cited in: Inflammopharmacology. 2024 Feb;32(1):733-745. [Abstract]

Ibuprofen-induced expression of GSDMD protein in C643 and OCUT-2C cells.
Cells

Prostaglandin 2α Promotes Autophagy and Mitochondrial Energy Production in Fish Hepatocytes. [Abstract]

2022 Jun 9;11(12):1870. PMID: 35740999
EMBO Rep

CDK inhibitor Palbociclib targets STING to alleviate autoinflammation. [Abstract]

2022 Jun 7;23(6):e53932. PMID: 35403787
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Int Immunopharmacol

Oxyphenbutazone suppresses non-canonical inflammasome activation and protects against LPS-induced sepsis. [Abstract]

2026 Aug 15:183:116873. PMID: 42150290
Int J Mol Sci

Singapore Grouper Iridovirus Disturbed Glycerophospholipids Homeostasis: Cytosolic Phospholipase A2 Was Essential for Virus Replication. [Abstract]

2021 Nov 22;22(22):12597. PMID: 34830477
Bioresour Technol Rep

2023 Nov 10, 101696.
Bioresour Technol Rep

2023 Dec, 24, 101619.
Sci Rep

Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation. [Abstract]

2020 Oct 2;10(1):16383. PMID: 33009446
Neuropharmacology

Malfunction of astrocyte and cholinergic input is involved in postoperative impairment of hippocampal synaptic plasticity and cognitive function. [Abstract]

2022 Oct 1:217:109191. PMID: 35835213
ACS Chem Neurosci

Identification of a Nonelectrophilic and Selective TRPA1 Agonist for Alleviation of Inflammatory Pain through Channel Desensitization. [Abstract]

2025 Sep 3;16(17):3257-3266. PMID: 40846466
J Neurosci

Acute Ongoing Nociception Delays Recovery of Consciousness from Sevoflurane Anesthesia via a Midbrain Circuit. [Abstract]

2024 Jul 17:e0740242024. PMID: 39019613
Reprod Toxicol

Zebrafish embryos as a teratogenicity screening tool to reduce potential birth defects. [Abstract]

2025 May:134:108895. PMID: 40097051
J Appl Toxicol

Differential impacts of nonsteroidal anti-inflammatory drugs on lifespan and healthspan in aged Caenorhabditis elegans. [Abstract]

2024 Oct;44(10):1528-1539. PMID: 38840409
Chemosphere

Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. [Abstract]

2019 Jun:225:378-387. PMID: 30884299

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (484.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.8478 mL

24.2389 mL

48.4778 mL

5 mM

0.9696 mL

4.8478 mL

9.6956 mL

10 mM

0.4848 mL

2.4239 mL

4.8478 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Noreen Y, et al. Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis. J Nat Prod. 1998 Jan;61(1):2-7. [Content Brief]

[2]. Hassan Akrami, et al. Inhibitory effect of ibuprofen on tumor survival and angiogenesis in gastric cancer cell. Tumour Biol. 2015 May;36(5):3237-43. [Content Brief]

[3]. Sharon M Rymut, et al. Ibuprofen regulation of microtubule dynamics in cystic fibrosis epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2016 Aug 1;311(2):L317-27. [Content Brief]

[4]. Emmanuelle Bignon, et al. Ibuprofen and ketoprofen potentiate UVA-induced cell death by a photosensitization process. Sci Rep. 2017 Aug 21;7(1):8885. [Content Brief]

[5]. Nathan D Pennock, et al. Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. J Immunother Cancer. 2018 Oct 1;6(1):98. [Content Brief]

[6]. Thomas Krøigård, et al. Protective effect of ibuprofen in a rat model of chronic oxaliplatin-induced peripheral neuropathy. Exp Brain Res. 2019 Oct;237(10):2645-2651. [Content Brief]

[7]. Sarah Ilkhanipour Rooney, et al. Ibuprofen Differentially Affects Supraspinatus Muscle and Tendon Adaptations to Exercise in a Rat Model. Am J Sports Med. 2016 Sep;44(9):2237-45. [Content Brief]

[8]. M W Konstan, et al. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis. Am Rev Respir Dis. 1990 Jan;141(1):186-92. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.8478 mL	24.2389 mL	48.4778 mL	121.1945 mL
	5 mM	0.9696 mL	4.8478 mL	9.6956 mL	24.2389 mL
	10 mM	0.4848 mL	2.4239 mL	4.8478 mL	12.1194 mL
	15 mM	0.3232 mL	1.6159 mL	3.2319 mL	8.0796 mL
	20 mM	0.2424 mL	1.2119 mL	2.4239 mL	6.0597 mL
	25 mM	0.1939 mL	0.9696 mL	1.9391 mL	4.8478 mL
	30 mM	0.1616 mL	0.8080 mL	1.6159 mL	4.0398 mL
	40 mM	0.1212 mL	0.6060 mL	1.2119 mL	3.0299 mL
	50 mM	0.0970 mL	0.4848 mL	0.9696 mL	2.4239 mL
	60 mM	0.0808 mL	0.4040 mL	0.8080 mL	2.0199 mL
	80 mM	0.0606 mL	0.3030 mL	0.6060 mL	1.5149 mL
	100 mM	0.0485 mL	0.2424 mL	0.4848 mL	1.2119 mL

Ibuprofen

23 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Ibuprofen

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

NMPA-Approved Drug Library

Pyroptosis Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Antiparasitic Compound library

Anti-Obesity Compound Library

Targeted Diversity Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Pediatric Drug Library

Antidepressant Compound Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

Nephrotoxicity Compound Library

Publications Citing Use of MedChemExpress (MCE) Ibuprofen

Alle COX Isoform-spezifische Produkte anzeigen

Alle Parasite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (23)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Ibuprofen Related Classifications

HY-78131 Related Classifications